A new analysis by a public health expert at the Hebrew University of Jerusalem has found that finasteride, a widely used treatment for hair loss, has been associated with depression and suicide for more than twenty years. Despite these long-standing concerns, neither regulators nor the drug’s manufacturer took meaningful action. Drawing on adverse event reports and health records from several countries, the review identifies a consistent pattern of psychiatric side effects linked to the drug. Even with growing evidence, both Merck and the FDA failed to launch necessary safety investigations. The author is now urging major reforms to the way medications are approved and monitored for long-term risks.
For more than two decades, finasteride has been prescribed to millions of men seeking to slow or reverse hair loss. Behind its cosmetic appeal, however, evidence has continued to emerge suggesting serious mental health consequences, including depression, anxiety, and in some cases, suicide.
Prof. Mayer Brezis of the Hebrew University of Jerusalem argues that both the medical community and regulators have repeatedly failed to protect the public by overlooking signs of psychiatric harm associated with the drug.
His review analyzed data from eight large studies published between 2017 and 2023. The findings show a clear trend: people who used finasteride were far more likely to experience mood disorders and suicidal thoughts than those who did not. This pattern appeared consistently across various national databases, including the FDA’s adverse event system and healthcare records from Sweden, Canada, and Israel.
“The evidence is no longer anecdotal,” said Prof. Brezis, a professor emeritus of medicine and public health. “We now see consistent patterns across diverse populations. And the consequences may have been tragic.”
The report estimates that hundreds of thousands of users may have suffered from finasteride-related depression, and that hundreds — possibly more — may have died by suicide. Originally approved by the FDA in 1997 for male pattern baldness, the drug has remained popular for its perceived safety and effectiveness, particularly among younger men. Critics say, however, that its risks were downplayed or ignored.
You must be logged in to post a comment.